University College London
United Kingdom
History
Founded in 2014, the Trisomy 21 Research Society (T21RS) laid the foundation for the Down Syndrome and Other Genetic Developmental Disorders Network. T21RS, a non-profit organisation with over 300 members worldwide, promotes research into Down syndrome and related neurodevelopmental disorders. The DSG2D Network emerged from this society to further stimulate translational research and develop treatments.
We will continue to build on previous work that helped to obtained several grants with research groups across Europe, including the European Union's Horizon 2020 programme Go-DS21, that is focussed on understanding gene dosage in Down syndrome and its relationship to comorbidities. We aim to publish reviews and guidance to better manage health issues associated with Down syndrome and other genetic syndromes associated with intellectual disabilities. Our members are also actively participating in the activities of the international Trisomy 21 Research Society (T21RS), such as a survey to determine the impact of vaccination to reduce the risk associated with COVID-19 in people with Down syndrome.
Members
| Member name | Institution | City | Country |
| Eugenio Barone | Sapienza University of Rome | Rome | Italy |
| Renata Bartesaghi | University of Bologna | Bologna | Italy |
| Rafael de la Torre Fornell | IMIM | Barcelona | Spain |
| Mara Dierssen | Centre for Genomic Regulation | Barcelona | Spain |
| Juan Fortea | Hospital de Sant Pau | Barcelona | Spain |
| Sandra Guidi | University of Bologna | Bologna | Italy |
| Maria Martinez de Lagran Cabredo | Centre of Genomic Regulation | Barcelona | Spain |
| Pietro Lio' | University of Cambridge | Cambridge | United Kingdom |
| Marzia Perluigi | Sapienza University of Rome | Rome | Italy |
| Marie-Claude Potier | Pitié-Salpêtrière Hospital | Paris | France |
| Fiorenza Stagni | University of Bologna | Bologna | Italy |
Publications
-
2018Faundez et al.
Translating molecular advances in Down syndrome and Fragile X syndrome into therapies
European Neuropsychopharmacology -
2016de la Torre et al.
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
The Lancet Neurology